IMV - IMV STOCK NEWS

IMV Inc. provides an update on its Phase 2B trials for MVP-S, showing significant progress in patient recruitment for VITALIZE and AVALON studies. VITALIZE, investigating MVP-S with Keytruda for DLBCL, is expected to yield first results by Q3 2022. AVALON has dosed its first patient, targeting platinum-resistant ovarian cancer, with early data anticipated in H1 2023. The company reported a net loss of $9.9 million for Q2 2022, increasing from $7.4 million YoY. As of June 30, 2022, IMV had $31.1 million in cash, projecting funds into Q2 2023.

IMV Inc. has announced plans to continue its existing at-the-market facility, allowing the sale of up to US$50 million in common shares. This follows an equity distribution agreement with Piper Sandler, which will act as the sales agent on the Nasdaq. The proceeds from the sale will fund general corporate needs, including research and clinical trial expenditures. The company has filed the necessary documentation to comply with both Canadian and U.S. regulations. The move is part of IMV's strategy to support its portfolio of immune-educating therapies.

IMV Inc. (NASDAQ: IMV) announced a conference call on August 11, 2022, at 8:00 a.m. ET to discuss its 2022 second quarter financial and operational results. The call is aimed at financial analysts, who can register via a provided link. A live audio webcast will also be available for others. IMV specializes in developing immune-educating therapies targeting solid and hematologic cancers through its DPX platform, with its lead candidate, maveropepimut-S (MVP-S), currently in clinical trials for multiple cancer types.

IMV Inc. (NASDAQ: IMV) has received a notice from Nasdaq indicating non-compliance with the minimum bid price of $1.00 per share over 30 business days, ending July 6, 2022. The Company has a 180-day Compliance Period, until January 3, 2023, to regain compliance by maintaining the minimum bid price for ten consecutive business days. If unsuccessful, it may seek an additional 180 days under specific conditions, including potential reverse stock splits. The notice does not immediately affect the Company’s operations or listing status on Nasdaq or TSX.

IMV Inc. announced the voting outcomes of its annual meeting held on June 29, 2022, where all resolutions, including the election of directors, were accepted. Shareholder voting percentages for candidates like Michael Bailey and Brittany Davison were notably high, with 99.11% and 99.32% approval, respectively. The meeting also approved the appointment of PricewaterhouseCoopers as independent auditor and an amendment to the deferred share unit plan increasing share reservation to 2 million. Former board chair Andrew Sheldon did not seek re-election, while Joy Bessenger left her position in an organizational shift.

IMV Inc. has successfully accessed the remaining $10 million under its $25 million debt facility with Horizon Technology Finance. This funding follows the milestone achievement of site activation in its Phase 2b AVALON trial for platinum-resistant ovarian cancer. The financing strengthens IMV's balance sheet, enabling continued development of its lead compound targeting Diffuse Large B-Cell Lymphoma (DLBCL) and ovarian cancer. The facility supports ongoing clinical developments and general working capital.

IMV Inc., a clinical-stage company focused on immune-educating therapies, announced its participation in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, FL. The executive team will present on May 25 at 9:30 a.m. ET, with a link to the presentation available on IMV's website. The company develops therapies utilizing its DPX platform, notably maveropepimut-S (MVP-S), targeting multiple cancers. MVP-S has shown clinical benefits in various cancer types and is in ongoing trials. More details can be found on IMV's official website.

IMV Inc. (Nasdaq: IMV) announced positive clinical results for MVP-S in bladder cancer at the AACR annual meeting, showing 2 confirmed complete responses and 3 partial responses among patients previously treated with checkpoint inhibitors. The treatment was well-tolerated, with mostly mild reactions and no severe adverse events. Financial results for Q1 2022 revealed cash of $28.7 million and a net loss of $10.5 million. The company is progressing with its clinical trials and expanding its pipeline, with key milestones expected in 2022 and 2023.

IMV Inc. (NASDAQ: IMV; TSX: IMV) announced a conference call scheduled for May 13, 2022, at 8:00 a.m. ET to discuss its 2022 first quarter financial and operational results. Interested parties can access the live audio webcast through IMV's website. The company is developing its DPX platform, which aims to treat both solid and hematologic cancers, with its lead candidate, maveropepimut-S (MVP-S), showing promise in various cancer indications.